What it is
When mood or worry after birth is not lifting, there are two main roads, and they can be walked together. Therapy postpartum means talking with someone trained in this season. Medication means antidepressants postpartum or newer drugs built for . Mothers search Zoloft breastfeeding, , and medication while nursing because they want to know what is safe. Your provider decides with you.
Therapy comes in several kinds. (CBT) works on the thoughts that drive mood. () works on the relationships and role shifts of new motherhood. Both have strong evidence.
Medication options include the , a family of antidepressants used for decades. Sertraline, sold as Zoloft, is the one most studied in nursing mothers. In 2023 it approved zuranolone, the first pill made for postpartum depression, taken for fourteen days.
What's typical
Therapy usually starts weekly. Many mothers feel some shift in four to six sessions, with a full course often eight to sixteen. SSRIs take two to six weeks to work and are usually taken for at least six to twelve months. Zuranolone is a two-week course, and in trials many mothers felt better within three days. Side effects exist for every option, and so does the risk of doing nothing. Untreated depression also reaches the baby, through sleep, feeding, and bonding.
What's known
ACOG, the AAP, and the Academy of Breastfeeding Medicine agree that most antidepressants are compatible with breastfeeding. , a free database from the National Library of Medicine, and the InfantRisk Center track what is known about every drug in milk. For SSRIs, the amount reaching the baby is very small, and decades of follow-up studies are reassuring. Zuranolone is newer; ask your provider what the current guidance on nursing says. Therapy has no drug risk and works as well as medication for mild to moderate depression. For severe depression, the combination works best.
What helps
- Write down your three biggest questions before the visit. 'Can I nurse on this.' 'How long until I feel it.' 'What if it doesn't work.'
- Ask your provider to check LactMed with you, right there in the room.
- Use the PSI provider directory to find a therapist who says 'perinatal.' Many take insurance or offer a sliding scale.
When to call someone
- Nowthoughts of ending your life or hurting yourself or the baby. Call or text 988, or call 911. Care can start the same day.
- Todayyou have stopped a medication on your own and feel worse, dizzy, or shaky. Stopping suddenly can cause withdrawal.
- Todayyour mood is past two weeks and not lifting. Call your provider or the Maternal Mental Health Hotline, 1-833-852-6262, for a list of options.
- At your next visityou want to understand your options before you need them. Ask for a plan.
What it is
When low mood or worry after birth does not lift, the main options fall into two groups that can be used together: and medication. The therapies with the strongest evidence are cognitive behavioral therapy (CBT), which works on the link between thoughts, behavior, and mood, and (), which works on relationships and the role changes of new motherhood. The medications are mostly antidepressants called (selective serotonin reuptake inhibitors), plus two newer drugs made for . is given by a slow infusion in a certified health care setting. is a pill used for a 14-day course. Both were approved by the U.S. Food and Drug Administration (FDA), in 2019 and 2023.
Why do these work? SSRIs raise the amount of serotonin, a chemical messenger, available between nerve cells, and the brain adapts over several weeks. Brexanolone and zuranolone act on a different system. They are lab-made versions of , a breakdown product of progesterone that calms the brain through GABA, its main braking signal. Allopregnanolone rises through pregnancy and falls fast after birth. One idea is that some brains handle that drop poorly. That idea is a hypothesis, not a proven cause. Therapy involves no drug exposure at all, which is one reason it is a first choice for many mothers.
What's typical
Therapy usually starts weekly. Many mothers notice a shift within four to six sessions, and a full course is often 8 to 16 sessions. SSRIs usually need two to six weeks to show their full effect, and clinical guidelines commonly suggest continuing for months after symptoms ease, often 6 to 12, to lower the chance of relapse. In the zuranolone trials, mothers began to feel better within about three days, and the main comparison with placebo was made at day 15 (Deligiannidis 2023). Every option has side effects. Sleepiness and dizziness are common with zuranolone, and its label warns about driving.
Doing nothing has costs too. About 1 in 8 mothers in the United States reports symptoms of postpartum depression (CDC). A major review found that untreated depression in the perinatal period is linked with poorer sleep, more difficult feeding, weaker bonding, and later emotional and behavior problems in children (Stein 2014, The Lancet).
What's known
ACOG's 2023 clinical practice guideline names psychotherapy and SSRIs as first-line options for . ACOG, the American Academy of Pediatrics, and the Academy of Breastfeeding Medicine agree that most antidepressants are compatible with breastfeeding. In a pooled analysis of nursing babies' blood levels, Weissman and colleagues (2004) found sertraline and paroxetine rarely detectable, while fluoxetine and citalopram showed up more often. , a free database from the National Library of Medicine, and the InfantRisk Center keep drug-by-drug summaries.
The evidence is uneven. Cochrane reviews (Dennis and Hodnett 2007; Molyneaux 2014) found good support for therapy, but only a few small trials of antidepressants specifically for postpartum depression. Two randomized trials of roughly 150 to 200 mothers each found zuranolone beat placebo (Deligiannidis 2021, 2023), but follow-up was short and nursing guidance is still developing. The current FDA label and LactMed are the places to check. For severe depression, many clinicians combine therapy and medication.
What helps
- Write down your three biggest questions before the visit, such as whether you can nurse on a medication, how long until you would feel it, and what the plan is if it does not work.
- Ask your provider to look up each drug in LactMed with you, right there in the room.
- Use the Postpartum Support International provider directory to find a therapist who lists perinatal mental health as a specialty. Many take insurance or offer sliding-scale fees.
- Ask whether your state has a perinatal psychiatry access line. These free phone services let your obstetric or primary care provider consult a psychiatrist about your care.
- If you are nursing and a medication is started, tell the baby's pediatrician the plan so that watching for changes in sleep or feeding is a shared job.
When to call someone
- Nowthoughts of ending your life or hurting yourself or the baby. Call or text 988, or call 911. Care can start the same day.
- Todayyou have stopped a medication on your own and feel worse, dizzy, or shaky. Stopping suddenly can cause discontinuation symptoms. Call your prescriber or pharmacist.
- Todayyour mood has been low or anxious for more than two weeks and is not lifting. Call your provider or the National Maternal Mental Health Hotline, 1-833-852-6262.
- At your next visityou want to understand your options before you need them. Ask for a written plan.
Written as a review for birthworkers and readers of papers. It describes practice; it does not instruct, and it carries no doses.
Overview
Postpartum depressive and anxiety disorders are managed with psychotherapy, pharmacotherapy, or both, selected by severity, prior response, patient preference, and feeding plans. ACOG Clinical Practice Guideline No. 5 (2023) names psychotherapy ( and ) and selective serotonin reuptake inhibitors as first-line options, and frames the decision as shared. The FDA approved (2019) and (2023) as the first drugs indicated specifically for . The central clinical problem is seldom whether to treat but how to weigh infant exposure through milk against the documented harms of untreated illness for mother and child.
Mechanism
block the serotonin transporter, raising synaptic serotonin acutely, but clinical response lags by two to six weeks, which implicates downstream adaptation in neuroplasticity rather than the acute change itself. That lag is established; the specific adaptations are still debated.
The neurosteroid hypothesis for postpartum depression centers on , a progesterone metabolite and positive allosteric modulator of receptors, including extrasynaptic delta-subunit receptors that mediate tonic inhibition. Levels rise across pregnancy and fall abruptly after delivery. In mice, Maguire and Mody (Neuron 2008) showed that receptor subunit expression adapts during pregnancy and that failure to recover afterward produces depressive-like behavior. In humans, Bloch and colleagues (American Journal of Psychiatry 2000) found that experimentally induced withdrawal of gonadal steroids provoked mood symptoms in women with a history of postpartum depression but not in controls, pointing to differential sensitivity rather than abnormal hormone levels. Brexanolone is allopregnanolone itself; zuranolone is an oral synthetic analog. Whether peripheral allopregnanolone levels track symptoms is inconsistent, so the model remains partly hypothesized.
Psychotherapy mechanisms are better described than proven. CBT targets cognitive appraisals and behavioral activation. targets role , interpersonal disputes, and grief, the domains most disturbed by new parenthood.
depends on a drug's molecular weight, lipid solubility, protein binding, , and infant oral absorption and clearance. Exposure is summarized as , the infant's weight-adjusted intake as a percentage of the maternal dose; about 10 percent is the conventional ceiling for concern (Bennett), and sertraline typically falls well below it per . Neonatal and preterm clearance is slower, so infant age and health modify risk.
Epidemiology
Pooled estimates place major or minor depression in roughly 19 percent of mothers within three months of birth, with major depression near 7 percent (Gavin 2005, meta-analysis of interview- and questionnaire-based studies). CDC surveillance (PRAMS) reports self-reported postpartum depressive symptoms in about 1 in 8 U.S. mothers, with state variation. Onset clusters in the first weeks to months, though DSM-5-TR restricts the peripartum-onset specifier to onset in pregnancy or within four weeks of delivery. Established risk factors include prior depression, anxiety in pregnancy, low , adverse life events, and thyroid dysfunction.
Treatment gaps are large. Cox and colleagues (2016, treatment cascade) estimated that only a minority of affected women reach any treatment and fewer still reach adequate treatment. Among screen-positive women, Wisner and colleagues (JAMA Psychiatry 2013, about 10,000 women) found that a notable share endorsed thoughts of self-harm and that roughly one in five of those meeting criteria had a bipolar-spectrum diagnosis, which matters for drug selection.
Clinical picture
Assessment starts with screening and diagnosis. The is the most studied instrument; an individual-participant meta-analysis (Levis 2020, BMJ) found a cutoff of 11 or higher gave a good balance of sensitivity and specificity for major depression. Item 10 asks about self-harm and is read separately. Clinicians apply DSM-5-TR criteria with the peripartum-onset specifier, grade severity, and ask about anxiety, obsessions, trauma, substance use, and past manic or hypomanic episodes, since antidepressant monotherapy can destabilize illness.
The differential includes the (common, peaking around day 3 to 5 and resolving within about two weeks, without functional impairment), thyroid dysfunction and anemia (checked by laboratory tests), sleep deprivation, anxiety disorders, obsessive-compulsive disorder, post-traumatic stress after birth, bipolar disorder, and , which is an emergency distinguished by confusion, hallucinations, delusions, and marked sleep loss. For drug choice in lactation, clinicians add infant age, prematurity, and the mother's prior response.
Evidence
Psychotherapy: O'Hara and colleagues (Archives of General Psychiatry 2000; randomized, 120 women) found IPT produced greater symptom reduction and recovery than a waitlist. Sockol and colleagues' meta-analysis (Clinical Psychology Review 2011) reported moderate to large effects for psychological treatments of , and the Cochrane review of Dennis and Hodnett (2007) was concordant. The USPSTF (2019) recommends counseling interventions for people at increased risk.
Antidepressants: Cochrane (Molyneaux 2014) identified few trials of small size, so the case for SSRIs in postpartum depression leans on the general depression literature plus lactation safety data. Weissman 2004 (American Journal of Psychiatry, pooled data on milk and infant serum) remains the anchor for relative infant levels; Berle and Spigset (2011) reviewed adverse infant events, which were rare and mostly mild case-level reports. Evidence for infant long-term neurodevelopment is observational and confounded by maternal illness.
Neurosteroids: Meltzer-Brody and colleagues (Lancet 2018) reported two placebo-controlled trials of brexanolone (about 245 women combined) with an advantage of roughly 4 to 5 points on the Hamilton Depression Rating Scale at 60 hours. Zuranolone trials (ROBIN, Deligiannidis 2021, n=153; SKYLARK, Deligiannidis 2023, n=196) each showed a difference near 4 points at day 15 and early separation by day 3; follow-up was about six weeks. Trials excluded many severe and comorbid presentations, durability beyond that is unknown, and the FDA label for zuranolone carries a boxed warning for impaired ability to drive. Lactation language in the label is more cautious than for SSRIs and should be checked in its current form.
Guidelines broadly agree on . They differ in emphasis: NICE (CG192) leads with psychological interventions, while U.S. guidance accepts medication earlier for moderate to severe illness.
Management landscape
As practiced, care is stepped. Mild illness is met with monitoring, psychotherapy, and . Moderate to severe illness is met with psychotherapy, an SSRI, or both, per ACOG. For severe illness, psychosis, or acute suicidality, urgent psychiatric evaluation and sometimes hospital admission are standard, and electroconvulsive therapy is an established option. Brexanolone is given as a 60-hour supervised infusion under a risk program because of excessive sedation and sudden loss of consciousness; zuranolone is a two-week oral course. Choice among SSRIs is commonly guided by prior response and by lactation data; ABM Protocol #18 and LactMed describe sertraline among the agents with consistently low infant levels. Clinicians usually ask the pediatrician to know the plan, and the infant is observed for sedation, poor feeding, or irritability. Continuation for roughly 6 to 12 months after remission is customary, and tapering is done under supervision because abrupt stopping produces a discontinuation syndrome. Many U.S. states fund perinatal psychiatry access programs, which let obstetric and primary care clinicians consult a psychiatrist by phone.
When to call someone
- Nowsuicidal thoughts or intent, or thoughts of harming yourself or the baby. Call or text 988, or call 911.
- Todaystopping a medication on your own followed by worse mood or discontinuation symptoms such as dizziness, nausea, irritability, or electric-shock sensations. Call your prescriber or pharmacist.
- Todaylow or anxious mood lasting beyond two weeks without lifting. Call your provider or the National Maternal Mental Health Hotline, 1-833-852-6262.
- At your next visitwanting to understand treatment options before they are needed. Ask for a written plan.
Open questions
How long treatment should continue after remission in postpartum depression is set largely by convention rather than by trials. There are no head-to-head trials comparing psychotherapy, SSRIs, and neurosteroids, and little is known about who responds to which. Nursing safety data for zuranolone and long-term infant neurodevelopment after milk exposure to any antidepressant remain limited. Whether the allopregnanolone model identifies a distinct biological subtype is still unsettled.
Key terms
Literature
- American College of Obstetricians and Gynecologists — Clinical Practice Guideline No. 5: Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum, 2023
- Deligiannidis KM et al. — Zuranolone for the treatment of postpartum depression (SKYLARK). JAMA Psychiatry 2023
- Deligiannidis KM et al. — Effect of zuranolone vs placebo in postpartum depression (ROBIN). JAMA Psychiatry 2021
- Meltzer-Brody S et al. — Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018
- Weissman AM et al. — Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. American Journal of Psychiatry 2004
- O'Hara MW et al. — Efficacy of interpersonal psychotherapy for postpartum depression. Archives of General Psychiatry 2000
- Molyneaux E et al. — Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2014
- Stein A et al. — Effects of perinatal mental disorders on the fetus and child. Lancet 2014
- Maguire J, Mody I — GABA(A)R plasticity during pregnancy: relevance to postnatal depression. Neuron 2008
- Wisner KL et al. — Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry 2013
- Academy of Breastfeeding Medicine — Clinical Protocol #18: Use of antidepressants in breastfeeding mothers, 2015 revision
Who helps
Tools: Birthworker Directory · My Birth Team
Related
- Postpartum depressionPostpartum: Mind
- Postpartum anxietyPostpartum: Mind
- Medications and breastfeeding: how to checkFeeding Your Baby
- When to get help, and who to call tonightPostpartum: Mind
- Support groups and peer supportPostpartum: Mind
What mothers here say
No one has posted under this topic yet. The first experience here will help the next mother who searches for it at 2 a.m.
Experiences and questions are their authors' own, not reviewed advice. The topic's steward lists the ones that help most in a credited digest once there is one. Unusual experiences stay, with a note.
Sources
- American College of Obstetricians and Gynecologists — Clinical practice guideline on treatment and management of mental health conditions during pregnancy and postpartum
- National Library of Medicine — LactMed drugs and lactation database
- InfantRisk Center — Antidepressants and breastfeeding
- U.S. Food and Drug Administration — Approval announcement for zuranolone for postpartum depression
- Academy of Breastfeeding Medicine — Clinical protocol on use of antidepressants in breastfeeding mothers
Sources are named, not yet linked. The steward verifies each one and adds the link.
Steward this topic
Birthworkers listed in our directory can claim a topic, verify its sources, and curate what mothers share here. Your name and credential go at the top of the page. Takes about an hour the first time.
Find your directory page